You just read:

I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in a Phase 1 Trial of the CD73 Antibody TJD5 in the U.S. in Patients with Advanced Solid Tumors

News provided by

I-Mab Biopharma

Aug 01, 2019, 22:15 ET